<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144499">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01758185</url>
  </required_header>
  <id_info>
    <org_study_id>BJCDPC-3</org_study_id>
    <nct_id>NCT01758185</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of Aleph Inactivated Split Influenza Vaccine</brief_title>
  <official_title>Phase 4 Safety and Immunogenicity Study of Aleph Inactivated Split Influenza Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Center for Disease Control and Prevention</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to evaluate the safety and immunogenicity of one inactivated
      split influenza vaccine, a primarily Chinese-marketed trivalent vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 3308 subjects were stratified equally into four age groups and receive either
      influenza vaccine or recombinant hepatitis b vaccine (seen as placebo). Systematic and local
      adverse reactions were reported for 28 d after the vaccination. Antibody levels were
      detected through hemagglutination inhibition assay before vaccination (Baseline) and 28d
      after the vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Incidence rate of adverse events of the inactivated split influenza vaccine</measure>
    <time_frame>two years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody titre of the inactivated split influenza vaccine</measure>
    <time_frame>two years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3308</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>recombinant hepatitis b vaccine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.5ml intramuscular</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aleph influenza vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5ml intramuscular</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant hepatitis b vaccine</intervention_name>
    <description>0.5ml intramuscular</description>
    <arm_group_label>recombinant hepatitis b vaccine</arm_group_label>
    <arm_group_label>Aleph influenza vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aleph influenza vaccine</intervention_name>
    <description>0.5ml intramuscular</description>
    <arm_group_label>recombinant hepatitis b vaccine</arm_group_label>
    <arm_group_label>Aleph influenza vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  more than three years in good healthy

        Exclusion Criteria:

          -  current infectious fever or acute disease

          -  upper respiratory infectious symptom within 6m

          -  a history of allergy

          -  laboratory confirmed influenza

          -  autoimmune disease

          -  have get influenza vaccine since 2008
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nianmin Shi, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chaoyang District Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhuolu County Center for Disease Control and Prevention</name>
      <address>
        <city>Zhangjiakou</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xinglong County Center for Disease Control and Prevention</name>
      <address>
        <city>Zhangjiakou</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 27, 2013</lastchanged_date>
  <firstreceived_date>December 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inactivated split influenza vaccine</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Safety</keyword>
  <keyword>Consistence</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
